These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 16085579)

  • 1. Potential and pitfalls of therapy with alpha-particles.
    Welch MJ
    J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
    [No Abstract]   [Full Text] [Related]  

  • 2. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise of targeted {alpha}-particle therapy.
    Mulford DA; Scheinberg DA; Jurcic JG
    J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astatine-211: production and availability.
    Zalutsky MR; Pruszynski M
    Curr Radiopharm; 2011 Jul; 4(3):177-85. PubMed ID: 22201707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alpha-radioimmunotherapy: a review of recent developments].
    Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
    Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia.
    Zalutsky MR; Schuster JM; Garg PK; Archer GE; Dewhirst MW; Bigner DD
    Recent Results Cancer Res; 1996; 141():101-22. PubMed ID: 8722422
    [No Abstract]   [Full Text] [Related]  

  • 7. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.
    Lucignani G
    Eur J Nucl Med Mol Imaging; 2008 Sep; 35(9):1729-33. PubMed ID: 18542953
    [No Abstract]   [Full Text] [Related]  

  • 8. Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?
    Allen BJ
    Immunotherapy; 2011 Apr; 3(4):455-8. PubMed ID: 21463184
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
    Zalutsky MR
    J Nucl Med; 2006 Aug; 47(8):1238-40. PubMed ID: 16882999
    [No Abstract]   [Full Text] [Related]  

  • 10. The ARRONAX project.
    Haddad F; Barbet J; Chatal JF
    Curr Radiopharm; 2011 Jul; 4(3):186-96. PubMed ID: 22201708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
    Vaidyanathan G; Zalutsky MR
    Curr Radiopharm; 2011 Oct; 4(4):283-94. PubMed ID: 22202151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
    Kozempel J; Mokhodoeva O; Vlk M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The radiation biology of radioimmunotherapy.
    Dixon KL
    Nucl Med Commun; 2003 Sep; 24(9):951-7. PubMed ID: 12960593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
    J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Appendix of Radionuclides Used in Targeted Alpha Therapy.
    Ferrier MG; Radchenko V
    J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S58-S65. PubMed ID: 31427258
    [No Abstract]   [Full Text] [Related]  

  • 16. Overcoming the obstacles to clinical evaluation of (211)At-labeled radiopharmaceuticals.
    Wilbur DS
    J Nucl Med; 2001 Oct; 42(10):1516-8. PubMed ID: 11585866
    [No Abstract]   [Full Text] [Related]  

  • 17. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
    Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
    Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At.
    Wesley JN; McGee EC; Garmestani K; Brechbiel MW; Yordanov AT; Wu C; Gansow OA; Eckelman WC; Bacher JD; Flynn M; Goldman CK; MacLin M; Schwartz UP; Jackson-White T; Phillip CM; Decker J; Waldmann TA
    Nucl Med Biol; 2004 Apr; 31(3):357-64. PubMed ID: 15028248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer radioimmunotherapy with alpha-emitting nuclides.
    Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The advantage of antibody cocktails for targeted alpha therapy depends on specific activity.
    Pasternack JB; Domogauer JD; Khullar A; Akudugu JM; Howell RW
    J Nucl Med; 2014 Dec; 55(12):2012-9. PubMed ID: 25349219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.